About
Avi has been with Forbion since 2006. Prior to that, he was a partner at Giza Venture Capital, an Israel-based diversified venture capital fund, managing over 600 million dollars. Avi established and headed the life science practice of the fund. The life science activity focused on medical technologies and drug development. Avi’s entrepreneurial work includes the founding and management of drug development as well as medical device companies. He is a co-founder and a Board member of BiolineRx (NASDAQ: BLRX; TASE: BLRX), a drug development company. Avi was the CEO and Chairman of Neovasc, an interventional cardiology company, leading it through a turn around to an acquisition. He is a co-founder and Executive Chairman of Biolojic Design, a rational therapeutic antibody design company. Avi is a physician who trained as a resident in psychiatry and a postdoctoral fellow in psychopharmacology, at Columbia Presbyterian Medical Center, New York. He served as the chief of the clinical unit of
Position in the VCSift Database
- • 29 investors at Forbion Capital Partners are tracked.
- • 421 investors hold the Venture Partner role in VCSift. Avi Molcho is one of them.
- • 610 investors are based in Israel.
Data sourced from 410,343 investor profiles. Updated May 2026.
Investment Focus
- Location
- Israel
Contact Information
Find more investors like Avi
Search Investors